Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data in patients with nail psoriasis from the phase IV POSITIVE study

被引：0
|
作者：
Weger, W. [1 ]
Gruber, B. [2 ]
Ratzinger, G. [3 ]
Sator, P-G [4 ]
机构：
[1] Med Univ Graz, Dept Dermatol & Venereol, Graz, Austria
[2] Klinikum Wels Grieskirchen, Dept Dermatol, Wels, Austria
[3] Med Univ Innsbruck, Dept Dermatol, Innsbruck, Austria
[4] Klin Hietzing, Dept Dermatol, Vienna, Austria
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
116
引用
收藏
页码：S352 / S352
页数：1
相关论文
共 26 条
  • [1] PATIENT-REPORTED WELL-BEING USING TILDRAKIZUMAB IN A REAL-WORLD SETTING: 52WEEK INTERIM DATA OF THE PHASE IV POSITIVE STUDY
    Sommer, Rachel
    Augustin, Matthias
    Reguiai, Ziad
    Gerdes, Sascha
    Dauden, Esteban
    Weger, Wolfgang
    Maul, Julia-Tatjana
    Laws, Philip
    Naldi, Luigi
    Ghislain, Pierre-Dominique
    Jong, Elke de
    Mburu, Sicily
    Koscielny, Volker
    Massana, Eric
    Kasujee, Ismail
    Mrowietz, Ulrich
    [J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [2] IMPACT OF PATIENT PSORIASIS ON PARTNER WELL-BEING IN A REAL-WORLD SETTING: 52-WEEK INTERIM DATA OF THE PHASE IV POSITIVE STUDY
    Mrowietz, Ulrich
    Sommer, Rachel
    Reguiai, Ziad
    Gerdes, Sascha
    Dauden, Esteban
    Weger, Wolfgang
    Maul, Julia-Tatjana
    Laws, Philip
    Naldi, Luigi
    Ghislain, Pierre-Dominique
    de Jong, Elke
    Mburu, Sicily
    Koscielny, Volker
    Massana, Eric
    Kasujee, Ismail
    Augustin, Matthias
    [J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [3] EFFECTIVENESS AND PATIENT-REPORTED WELLBEING OF TILDRAKIZUMAB IN PATIENTS WITH NAIL PSORIASIS: 52-WEEK RESULTS FROM THE PHASE IV POSITIVE STUDY
    Weger, Wolfgang
    Gruber, Barbara
    Ratzinger, Gudrun
    Sator, Paul-Gunther
    [J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [4] Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis
    Bhatia, Neal
    Heim, Jayme
    Schenkel, Brad
    Vasquez, J. Gabriel
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [5] Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)
    Augustin, Matthias
    Sommer, Rachel
    Dauden, Esteban
    Laws, Philip
    de Jong, Elke
    Fabbrocini, Gabriella
    Naldi, Luigi
    Navarini, Alexander
    Lambert, Jo
    Reguiai, Ziad
    Gerdes, Sascha
    Massana, Eric
    Obis, Teresa
    Kasujee, Ismail
    Mrowietz, Ulrich
    [J]. BMJ OPEN, 2023, 13 (02):
  • [6] A phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis
    Heim, Jayme
    Vasquez, J. Gabriel
    Beute, Paulita
    Torres, Monique
    Rozzo, Stephen J.
    Bhatia, Neal
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB132 - AB132
  • [7] A Phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis
    Heim, Jayme
    Vasquez, J. Gabriel
    Beute, Paulita
    Torres, Monique
    Rozzo, Stephen J.
    Bhatia, Neal
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 6 - 6
  • [8] Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: Week 28 interim analysis of a phase 4 study
    Bhatia, Neal
    Heim, Jayme
    Torres, Monique
    Beute, Paulita
    Rozzo, Stephen J.
    Vasquez, J. Gabriel
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB199 - AB199
  • [9] Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: Week 28 interim analysis of a Phase 4 study
    Bhatia, Neal
    Heim, Jayme
    Torres, Monique
    Beute, Paulita
    Rozzo, Stephen J.
    Vasquez, J. Gabriel
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 6 - 7
  • [10] QUALITY OF LIFE AND TREATMENT SATISFACTION WITH TILDRAKIZUMAB IN MODERATE-TO-SEVERE PSORIASIS PATIENTS: 52-WEEK INTERIM DATA OF THE REAL-WORLD POSITIVE STUDY
    Augustin, Matthias
    Sommer, Raquel
    Reguiai, Ziad
    Gerdes, Sascha
    Dauden, Esteban
    Weger, Wolfgang
    Maul, Julia-Tatjana
    Laws, Philip
    Naldi, Luigi
    Ghislain, Pierre-Dominique
    de Jong, Elke
    Mburu, Sicily
    Koscielny, Volker
    Massana, Eric
    Kasujee, Ismail
    Mrowietz, Ulrich
    [J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
123